Terminal-Restriction Fragment Length Polymorphism (T-RFLP) Analysis for Changes in the Gut Microbiota Profiles of Indomethacin- and Rebamipide-Treated Mice
Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally...
Saved in:
| Published in: | Digestion Vol. 86; no. 3; pp. 250 - 257 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Basel, Switzerland
S. Karger AG
01.01.2012
|
| Subjects: | |
| ISSN: | 0012-2823, 1421-9867, 1421-9867 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion. Results: T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone. Conclusion: The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. |
|---|---|
| AbstractList | We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis.
Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion.
T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone.
The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion. Results: T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone. Conclusion: The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion. Results: T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone. Conclusion: The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. Copyright [copy 2012 S. Karger AG, Basel We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis.BACKGROUND/AIMSWe investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis.Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion.MATERIALS AND METHODSFemale C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion.T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone.RESULTST-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone.The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota.CONCLUSIONThe combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion. Results: T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone. Conclusion: The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota. Copyright © 2012 S. Karger AG, Basel [PUBLICATION ABSTRACT] |
| Author | Imaeda, Hirotsugu Andoh, Akira Kasumi, Eiji Takahashi, Kenichiro Fujimoto, Takehide Fujiyama, Yoshihide |
| Author_xml | – sequence: 1 givenname: Hirotsugu surname: Imaeda fullname: Imaeda, Hirotsugu – sequence: 2 givenname: Takehide surname: Fujimoto fullname: Fujimoto, Takehide – sequence: 3 givenname: Kenichiro surname: Takahashi fullname: Takahashi, Kenichiro – sequence: 4 givenname: Eiji surname: Kasumi fullname: Kasumi, Eiji – sequence: 5 givenname: Yoshihide surname: Fujiyama fullname: Fujiyama, Yoshihide – sequence: 6 givenname: Akira surname: Andoh fullname: Andoh, Akira email: andoh@belle.shiga-med.ac.jp |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22964750$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkbFu2zAQhokiReOkHboXBYEuyaCGpESJHAOjTgK4qGG4s0BRJ4upRLokNfhZ-rKlYcdDUKDT4XDff8P3X6EL6ywg9JGSr5RyeUcIyQvKiXiDZrRgNJOirC7QjBDKMiZYfomuQng-rLLI36FLxmRZVJzM0J8N-NFYNWRrCNEbHY2zeOHVdgQb8RLsNvZ45Yb96PyuN2HEN5tsvViubvF9iu2DCbhzHs97ZbcQsLE49oAfpoi_G-1dY1xUeOVdZ4Z0dh1-sq0bIfZKG5thZVu8hkaNZmdayDYeVIT2kIX36G2nhgAfTvMa_Vx828wfs-WPh6f5_TLTRZ7HrJCNFDkRRVtJDq2oZEfbjsmqEbRQvGGqzUmheSlLphVXDZNaVVBqkSvJG5pfo5vj3513v6ekoR5N0DAMyoKbQk0rnhyKSuT_RylLXhkjZUK_vEKf3eSTskQxSYUsJReJ-nyipmaEtt55Myq_r18aSsDtEUguQ_DQnRFK6kP79bn9xN69YrWJ6tBo9MoM_0x8OiZ-Kb8Ff_59Ov8F0-y4Mg |
| CODEN | DIGEBW |
| CitedBy_id | crossref_primary_10_3390_ijms20204990 crossref_primary_10_3390_cells13090770 crossref_primary_10_1371_journal_pone_0245995 crossref_primary_10_1016_j_crohns_2014_02_001 crossref_primary_10_1371_journal_pone_0138293 crossref_primary_10_1038_s41598_017_13999_5 crossref_primary_10_3389_fphar_2022_818877 crossref_primary_10_1039_D4FO00539B crossref_primary_10_1038_srep40317 crossref_primary_10_1371_journal_pone_0122330 crossref_primary_10_1093_rheumatology_keaa316 crossref_primary_10_1007_s10620_015_3662_4 crossref_primary_10_1016_j_pharmthera_2022_108327 crossref_primary_10_1016_j_intimp_2020_107136 crossref_primary_10_1159_000452356 |
| Cites_doi | 10.1126%2Fscience.1058709 10.1046%2Fj.1365-2249.1999.01038.x 10.1053%2Fj.gastro.2007.11.059 10.1128%2FAEM.69.2.1251-1262.2003 10.1007%2Fs00535-007-2076-2 10.1099%2Fjmm.0.04991-0 10.1152%2Fphysrev.00004.2008 10.1111%2Fj.1574-6968.2006.00171.x 10.1007%2Fs00535-007-2155-4 10.1111%2Fj.1574-6941.2003.tb01040.x 10.1099%2Fjmm.0.45935-0 10.1016%2FS1542-3565%2804%2900619-6 10.1007%2Fs00535-010-0332-3 10.1053%2Fj.gastro.2005.03.020 10.1006%2Fphrs.1999.0550 10.1016%2FS0140-6736%2803%2912489-0 10.2174%2F138161209788489186 10.1136%2Fgut.2007.125963 10.1046%2Fj.1440-1746.2001.02592.x 10.1053%2Fj.gastro.2011.06.075 10.1126%2Fscience.1198469 10.1126%2Fscience.1110591 10.1128%2FAEM.66.8.3616-3620.2000 10.1016%2Fj.mimet.2006.09.006 10.1124%2Fjpet.300.3.754 10.1016%2F0090-6980%2877%2990178-2 10.1586%2Fegh.10.25 10.1016%2Fj.mimet.2004.12.009 10.1007%2Fs00535-010-0368-4 10.1007%2Fs00253-008-1565-4 |
| ContentType | Journal Article |
| Copyright | 2012 S. Karger AG, Basel Copyright © 2012 S. Karger AG, Basel. Copyright (c) 2012 S. Karger AG, Basel |
| Copyright_xml | – notice: 2012 S. Karger AG, Basel – notice: Copyright © 2012 S. Karger AG, Basel. – notice: Copyright (c) 2012 S. Karger AG, Basel |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS S0X 7X8 7T7 8FD C1K FR3 P64 |
| DOI | 10.1159/000341508 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China SIRS Editorial MEDLINE - Academic Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE CrossRef Engineering Research Database MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1421-9867 |
| EndPage | 257 |
| ExternalDocumentID | 2897755071 22964750 10_1159_000341508 341508 |
| Genre | Journal Article Comparative Study |
| GroupedDBID | --- .55 .GJ 0R~ 0~5 0~B 29G 30W 327 34G 36B 39C 3O. 3V. 4.4 53G 5GY 5RE 7X7 88E 8AO 8FI 8FJ 8UI AAYIC AAYJJ ABJNI ABPAZ ABUWG ACGFS ACPRK ACPSR ADAGL ADBBV AENEX AEYAO AFFNX AFJJK AFKRA AFOSN AHMBA AI. ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS APPQY AZPMC BENPR BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 E0A EBS EJD EMB EMOBN F5P FB. FYUFA HMCUK HZ~ IY7 KUZGX L7B M1P N9A O1H O9- PQQKQ PROAC PSQYO RIG RKO RXVBD S0X SV3 UJ6 UKHRP VH1 X7M ZGI ZXP AAYXX ABBTS ABWCG ACQXL AFFHD AFSIO AHFRZ CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7QP 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7T7 8FD C1K FR3 P64 |
| ID | FETCH-LOGICAL-c433t-49b983084d795ed879f1df297b814a5b2ad304c56962ca5ab29ca7e6c83a95b13 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000310717600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0012-2823 1421-9867 |
| IngestDate | Tue Oct 07 09:20:09 EDT 2025 Wed Oct 01 13:26:33 EDT 2025 Mon Oct 06 16:57:20 EDT 2025 Thu Apr 03 07:03:35 EDT 2025 Tue Nov 18 22:09:34 EST 2025 Sat Nov 29 07:57:34 EST 2025 Thu Aug 29 12:04:38 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Nonsteroidal anti-inflammatory drugs Terminal-restriction fragment length polymorphism 16S ribosomal RNA BslI digestion |
| Language | English |
| License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses Copyright © 2012 S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c433t-49b983084d795ed879f1df297b814a5b2ad304c56962ca5ab29ca7e6c83a95b13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 22964750 |
| PQID | 1291896958 |
| PQPubID | 2207 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1758238783 pubmed_primary_22964750 crossref_primary_10_1159_000341508 crossref_citationtrail_10_1159_000341508 proquest_miscellaneous_1124752206 karger_primary_341508 proquest_journals_1291896958 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-01 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
| PublicationTitle | Digestion |
| PublicationTitleAlternate | Digestion |
| PublicationYear | 2012 |
| Publisher | S. Karger AG |
| Publisher_xml | – name: S. Karger AG |
| References | Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172–1178.1588710110.1053%2Fj.gastro.2005.03.020 Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H: Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008;43:270–276.1845884210.1007%2Fs00535-007-2155-4 Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y: Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. Microbiol Immunol 1996;40:553–560. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577–594.1824222210.1053%2Fj.gastro.2007.11.059 Hooper LV, Gordon JI: Commensal host-bacterial relationships in the gut. Science 2001;292:1115–1118.1135206810.1126%2Fscience.1058709 Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K: Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999;40:517–524.1066095110.1006%2Fphrs.1999.0550 Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314–1322, 1322.e1-5.10.1053%2Fj.gastro.2011.06.075 Andoh A, Benno Y, Kanauchi O, Fujiyama Y: Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des 2009;15:2066–2073.10.2174%2F138161209788489186 Nagashima K, Hisada T, Sato M, Mochizuki J: Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003;69:1251–1262.10.1128%2FAEM.69.2.1251-1262.2003 Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov, II, Umesaki Y, Itoh K, Honda K: Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337–341.10.1126%2Fscience.1198469</pub-id><pub-id pub-id-type="pmid">21205640 Naito Y, Yoshikawa T: Rebamipide: A gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010;4:261–270.10.1586%2Fegh.10.25 Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512–519.1258396110.1016%2FS0140-6736%2803%2912489-0 Hayashi H, Sakamoto M, Kitahara M, Benno Y: Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S RRNA gene library. FEMS Microbiol Lett 2006;257:202–207.10.1111%2Fj.1574-6968.2006.00171.x Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T: Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008;57:181–187.1763908610.1136%2Fgut.2007.125963 Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA: Diversity of the human intestinal microbial flora. Science 2005;308:1635–1638.1583171810.1126%2Fscience.1110591 Schutte UM, Abdo Z, Bent SJ, Shyu C, Williams CJ, Pierson JD, Forney LJ: Advances in the use of terminal restriction fragment length polymorphism analysis of 16S RRNA genes to characterize microbial communities. Appl Microbiol Biotechnol 2008;80:365–380.10.1007%2Fs00253-008-1565-4 Matsumoto M, Sakamoto M, Hayashi H, Benno Y: Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Methods 2005;61:305–319.10.1016%2Fj.mimet.2004.12.009 Dean-Ross D, Mills AL: Bacterial community structure and function along a heavy metal gradient. Appl Environ Microbiol 1989;55:2002–2009. Wallace JL: Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev 2008;88:1547–1565.1892318910.1152%2Fphysrev.00004.2008 Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K: Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007;42:690–693.1770113310.1007%2Fs00535-007-2076-2 Sakamoto M, Hayashi H, Benno Y: Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 2003;47:133–142. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011;46:479–486.10.1007%2Fs00535-010-0368-4 Li F, Hullar MA, Lampe JW: Optimization of terminal restriction fragment polymorphism analysis of human gut microbiota. J Microbiol Methods 2007;68:303–311.10.1016%2Fj.mimet.2006.09.006 Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, Bamba T: Counter-regulatory effect of sodium butyrate on tumour necrosis factor-α-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999;118:23–29.10.1046%2Fj.1365-2249.1999.01038.x Hill TC, Walsh KA, Harris JA, Moffett BF: Using ecological diversity measures with bacterial communities. FEMS Microbiol Ecol 2003;43:1–11.10.1111%2Fj.1574-6941.2003.tb01040.x</pub-id><pub-id pub-id-type="pmid">19719691 Robert A, Asano T: Resistance of germ-free rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333–341.33140110.1016%2F0090-6980%2877%2990178-2 Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–141.1570404710.1016%2FS1542-3565%2804%2900619-6 Tanaka A, Hase S, Miyazawa T, Takeuchi K: Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754–761.1186177810.1124%2Fjpet.300.3.754 Marsh TL, Saxman P, Cole J, Tiedje J: Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. Appl Environ Microbiol 2000;66:3616–3620.10.1128%2FAEM.66.8.3616-3620.2000 Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998;43:5S-13S.9753220 Hayashi H, Takahashi R, Nishi T, Sakamoto M, Benno Y: Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S RRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol 2005;54:1093–1101.10.1099%2Fjmm.0.45935-0 Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K: Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001;16:1112–1119.1168683710.1046%2Fj.1440-1746.2001.02592.x Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011;46:57–64.10.1007%2Fs00535-010-0332-3 Sakamoto M, Takeuchi Y, Umeda M, Ishikawa I, Benno Y: Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis. J Med Microbiol 2003;52:79–89.10.1099%2Fjmm.0.04991-0 ref13 ref12 ref15 ref14 ref30 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – reference: Matsumoto M, Sakamoto M, Hayashi H, Benno Y: Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Methods 2005;61:305–319.10.1016%2Fj.mimet.2004.12.009 – reference: Hill TC, Walsh KA, Harris JA, Moffett BF: Using ecological diversity measures with bacterial communities. FEMS Microbiol Ecol 2003;43:1–11.10.1111%2Fj.1574-6941.2003.tb01040.x</pub-id><pub-id pub-id-type="pmid">19719691 – reference: Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998;43:5S-13S.9753220 – reference: Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K: Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001;16:1112–1119.1168683710.1046%2Fj.1440-1746.2001.02592.x – reference: Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172–1178.1588710110.1053%2Fj.gastro.2005.03.020 – reference: Marsh TL, Saxman P, Cole J, Tiedje J: Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. Appl Environ Microbiol 2000;66:3616–3620.10.1128%2FAEM.66.8.3616-3620.2000 – reference: Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H: Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008;43:270–276.1845884210.1007%2Fs00535-007-2155-4 – reference: Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011;46:479–486.10.1007%2Fs00535-010-0368-4 – reference: Schutte UM, Abdo Z, Bent SJ, Shyu C, Williams CJ, Pierson JD, Forney LJ: Advances in the use of terminal restriction fragment length polymorphism analysis of 16S RRNA genes to characterize microbial communities. Appl Microbiol Biotechnol 2008;80:365–380.10.1007%2Fs00253-008-1565-4 – reference: Hooper LV, Gordon JI: Commensal host-bacterial relationships in the gut. Science 2001;292:1115–1118.1135206810.1126%2Fscience.1058709 – reference: Wallace JL: Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev 2008;88:1547–1565.1892318910.1152%2Fphysrev.00004.2008 – reference: Tanaka A, Hase S, Miyazawa T, Takeuchi K: Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754–761.1186177810.1124%2Fjpet.300.3.754 – reference: Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K: Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007;42:690–693.1770113310.1007%2Fs00535-007-2076-2 – reference: Sakamoto M, Hayashi H, Benno Y: Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 2003;47:133–142. – reference: Dean-Ross D, Mills AL: Bacterial community structure and function along a heavy metal gradient. Appl Environ Microbiol 1989;55:2002–2009. – reference: Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314–1322, 1322.e1-5.10.1053%2Fj.gastro.2011.06.075 – reference: Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T: Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008;57:181–187.1763908610.1136%2Fgut.2007.125963 – reference: Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y: Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. Microbiol Immunol 1996;40:553–560. – reference: Li F, Hullar MA, Lampe JW: Optimization of terminal restriction fragment polymorphism analysis of human gut microbiota. J Microbiol Methods 2007;68:303–311.10.1016%2Fj.mimet.2006.09.006 – reference: Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov, II, Umesaki Y, Itoh K, Honda K: Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337–341.10.1126%2Fscience.1198469</pub-id><pub-id pub-id-type="pmid">21205640 – reference: Naito Y, Yoshikawa T: Rebamipide: A gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010;4:261–270.10.1586%2Fegh.10.25 – reference: Sakamoto M, Takeuchi Y, Umeda M, Ishikawa I, Benno Y: Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis. J Med Microbiol 2003;52:79–89.10.1099%2Fjmm.0.04991-0 – reference: Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, Bamba T: Counter-regulatory effect of sodium butyrate on tumour necrosis factor-α-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999;118:23–29.10.1046%2Fj.1365-2249.1999.01038.x – reference: Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–141.1570404710.1016%2FS1542-3565%2804%2900619-6 – reference: Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA: Diversity of the human intestinal microbial flora. Science 2005;308:1635–1638.1583171810.1126%2Fscience.1110591 – reference: Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011;46:57–64.10.1007%2Fs00535-010-0332-3 – reference: Nagashima K, Hisada T, Sato M, Mochizuki J: Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003;69:1251–1262.10.1128%2FAEM.69.2.1251-1262.2003 – reference: Andoh A, Benno Y, Kanauchi O, Fujiyama Y: Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des 2009;15:2066–2073.10.2174%2F138161209788489186 – reference: Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577–594.1824222210.1053%2Fj.gastro.2007.11.059 – reference: Robert A, Asano T: Resistance of germ-free rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333–341.33140110.1016%2F0090-6980%2877%2990178-2 – reference: Hayashi H, Sakamoto M, Kitahara M, Benno Y: Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S RRNA gene library. FEMS Microbiol Lett 2006;257:202–207.10.1111%2Fj.1574-6968.2006.00171.x – reference: Hayashi H, Takahashi R, Nishi T, Sakamoto M, Benno Y: Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S RRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol 2005;54:1093–1101.10.1099%2Fjmm.0.45935-0 – reference: Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512–519.1258396110.1016%2FS0140-6736%2803%2912489-0 – reference: Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K: Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999;40:517–524.1066095110.1006%2Fphrs.1999.0550 – ident: ref14 doi: 10.1126%2Fscience.1058709 – ident: ref30 doi: 10.1046%2Fj.1365-2249.1999.01038.x – ident: ref16 doi: 10.1053%2Fj.gastro.2007.11.059 – ident: ref25 doi: 10.1128%2FAEM.69.2.1251-1262.2003 – ident: ref9 doi: 10.1007%2Fs00535-007-2076-2 – ident: ref19 doi: 10.1099%2Fjmm.0.04991-0 – ident: ref4 doi: 10.1152%2Fphysrev.00004.2008 – ident: ref18 doi: 10.1111%2Fj.1574-6968.2006.00171.x – ident: ref11 doi: 10.1007%2Fs00535-007-2155-4 – ident: ref27 doi: 10.1111%2Fj.1574-6941.2003.tb01040.x – ident: ref23 doi: 10.1099%2Fjmm.0.45935-0 – ident: ref2 doi: 10.1016%2FS1542-3565%2804%2900619-6 – ident: ref12 doi: 10.1007%2Fs00535-010-0332-3 – ident: ref3 doi: 10.1053%2Fj.gastro.2005.03.020 – ident: ref7 doi: 10.1006%2Fphrs.1999.0550 – ident: ref15 doi: 10.1016%2FS0140-6736%2803%2912489-0 – ident: ref28 doi: 10.2174%2F138161209788489186 – ident: ref8 doi: 10.1136%2Fgut.2007.125963 – ident: ref13 doi: 10.1046%2Fj.1440-1746.2001.02592.x – ident: ref1 doi: 10.1053%2Fj.gastro.2011.06.075 – ident: ref29 doi: 10.1126%2Fscience.1198469 – ident: ref17 doi: 10.1126%2Fscience.1110591 – ident: ref24 doi: 10.1128%2FAEM.66.8.3616-3620.2000 – ident: ref20 doi: 10.1016%2Fj.mimet.2006.09.006 – ident: ref5 doi: 10.1124%2Fjpet.300.3.754 – ident: ref6 doi: 10.1016%2F0090-6980%2877%2990178-2 – ident: ref10 doi: 10.1586%2Fegh.10.25 – ident: ref26 doi: 10.1016%2Fj.mimet.2004.12.009 – ident: ref21 doi: 10.1007%2Fs00535-010-0368-4 – ident: ref22 doi: 10.1007%2Fs00253-008-1565-4 |
| SSID | ssj0012943 |
| Score | 2.0459511 |
| Snippet | Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism... We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis.... We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP)... |
| SourceID | proquest pubmed crossref karger |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 250 |
| SubjectTerms | Alanine - analogs & derivatives Alanine - toxicity Animals Bacteroides Cecum - drug effects Cecum - microbiology Cecum - pathology Clostridiaceae Disease Models, Animal DNA, Bacterial - genetics Drug Therapy, Combination Female Gastrointestinal Tract - drug effects Gastrointestinal Tract - microbiology Gastrointestinal Tract - pathology Ileum - drug effects Ileum - microbiology Ileum - pathology Indomethacin - toxicity Metagenome - genetics Mice Mice, Inbred C57BL Original Paper Polymorphism, Restriction Fragment Length Prevotella Quinolones - toxicity |
| Title | Terminal-Restriction Fragment Length Polymorphism (T-RFLP) Analysis for Changes in the Gut Microbiota Profiles of Indomethacin- and Rebamipide-Treated Mice |
| URI | https://karger.com/doi/10.1159/000341508 https://www.ncbi.nlm.nih.gov/pubmed/22964750 https://www.proquest.com/docview/1291896958 https://www.proquest.com/docview/1124752206 https://www.proquest.com/docview/1758238783 |
| Volume | 86 |
| WOSCitedRecordID | wos000310717600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1421-9867 dateEnd: 20151130 omitProxy: false ssIdentifier: ssj0012943 issn: 0012-2823 databaseCode: 7X7 dateStart: 19960101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1421-9867 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0012943 issn: 0012-2823 databaseCode: BENPR dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagrRAXHn3QhVIZhFA5WE3iOLFPqKAuILWraLVIe1s5fpSI3aTdZJH6W_izjJ0HQoJekKIckoliaTyezzPj-RB6owMVxNYaYlxxWGxSSgC1gl0FwuYhU1qG1pNNpJMJn89F1gXc6q6ssl8T_UKtK-Vi5Kfgl0IuEsH4--sb4lijXHa1o9C4j7YdbbbrnZ_Ohw0XfNJVzYXuCHJEu85C4MFPfWMW1wv9D3-0892VX6__jTa91xk__t_xPkGPOryJz9oJ8hTdM-Uu2jsrYa-9usVvsa8A9aH1XfTgsku076Gfs7ZIZkmmxjF7-NMPGFDulYsm4gtTXjXfcFYtb1cVaKqoV_hkRqbji-wd7vucYMDDuD29UOOixAA18adNgy-LtvlTI3HWMobXuLL4S6krx2ctYQQEy1JjUL1cFY7ClswctjXafWv20dfx-ezjZ9LxOBAVU9qQWOSC04DHOhXMaJ4KG2obiTTnYSxZHklNg1ixRCSRkkzmkVAyNYniVAqWh_QAbZVVaQ4RVjFjUtk8UJzFoaTCgtYjRW3CLCxWbIROem0uVNfk3HFtLBd-s8PEYlD8CL0eRK_bzh5_E9pvp8Qg0j8_6rW-6Iy-XvxW-Qi9Gl6DubocjCxNtQEZwFMpYN4guUMG9nCApFJOR-hZO_uG30cuTQ4o7_ndA3iBHkaBL7qB6whtNeuNeYl21I-mqNfH3kr8nR-j7Q_nk2z6C3teG4A |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1db9MwFL0aYwJe-NgGFAYYBGg8RMuXY_sBoQkYq9ZW1VSkvgXHsUdFm4wmBfW38B_4jVznCyHB3vaA1Kf2trWS4-tz4-N7AJ6nrnJDY7SjrTgs1CxwkLXivHKFSTyqUumZymyCjUZ8OhXjDfjZnoWxsso2J1aJOs2VfUZ-gOuSx0UkKH9z_tWxrlF2d7W10KhhcaLX37FkK1733-H9feH7R-8nb4-dxlXAUWEQlE4oEsEDl4cpE1SnnAnjpcYXLOFeKGniyxRLfEUjEflKUpn4QkmmI8UDKWjiBfi7V-Aq5nFmJWRs2hV4OMRGpefZI89-0HQyQsZwUDWCsb3X_1j_tr5Yuffy3-y2WuWObv1v1-c23Gz4NDmsJ8Ad2NDZNuwcZrLMF2vyklQK12rrYBuuDRshwQ78mNQioLlzqq1zSXW6gyCLP7NPS8lAZ2flZzLO5-tFjkicFQuyP3FOjwbjV6Tt40KQ75P6dEZBZhlBKk0-rEoynNXNrUpJxrUjekFyQ_pZmlu_bokjcIjMUoLQlouZteh1Jpa769R-V-_Cx0u5YndhM8szfR-ICimVyiSu4jT0ZCAMZ6GvAhNRg8mY9mC_RU-smibu1ktkHlfFHBVxB7QePOtCz-vOJX8L2q0h2IW07--1KIubpFbEvyHWg6fdx5iO7B6TzHS-whjkiww5vRtdEIM1KjJFxoMe3KvR3v29b2UAyGIfXDyAJ3D9eDIcxIP-6OQh3PDdSmCErz3YLJcr_Qi21LdyViwfVzOUwKfLhvwvptx1Ug |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1db9MwFLXGmKa98LENKAwwCNB4iJrEcWw_IDQxCtW6qpqK1LfgOPYW0SajSUH9LfwTfh3X-UJIsLc9IPWpvW2t5Pj63Pj4HoReJK5yA2O0o604LNCMOMBaYV65wsQeVYn0TGU2wcZjPpuJyQb62Z6FsbLKNidWiTrJlX1G3od1yeMiFJT3TSOLmBwP3l5-dayDlN1pbe00aoic6PV3KN-KN8NjuNcvfX_wfvruo9M4DDgqIKR0AhELTlweJExQnXAmjJcYX7CYe4GksS8TKPcVDUXoK0ll7AslmQ4VJ1LQ2CPwuzfQTUYIs7YRbNYVezDcRrHn2ePPPmm6GgF76FdNYWwf9j_Wwq0vVvq9_DfTrVa8we3_-VrdQbcano2P6olxF23obBftHWWyzBdr_ApXytdqS2EXbZ82AoM99GNai4Pmzpm2jibVqQ8M7P7cPkXFI52dlxd4ks_XixwQmhYLfDh1zgajyWvc9nfBUAfg-tRGgdMMA8XGH1YlPk3rplelxJPaKb3AucHDLMmtj7eEEThYZgkGyMtFaq17nanl9Dqx39X76NO1XLF7aDPLM_0AYRVQKpWJXcVp4EkiDGeBr4gJqYEkTXvosEVSpJrm7tZjZB5VRR4VUQe6HnrehV7WHU3-FrRfw7ELad8_aBEXNcmuiH7DrYeedR9DmrJ7TzLT-QpigEcy4PpueEUM1K7AIBknPXS_Rn73976VBwC7fXj1AJ6ibUB6NBqOTx6hHd-tdEfwOkCb5XKlH6Mt9a1Mi-WTarJi9Pm6Ef8LTSR-Bg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Terminal-Restriction+Fragment+Length+Polymorphism+%28T-RFLP%29+Analysis+for+Changes+in+the+Gut+Microbiota+Profiles+of+Indomethacin-+and+Rebamipide-Treated+Mice&rft.jtitle=Digestion&rft.au=Imaeda%2C+Hirotsugu&rft.au=Fujimoto%2C+Takehide&rft.au=Takahashi%2C+Kenichiro&rft.au=Kasumi%2C+Eiji&rft.date=2012-01-01&rft.issn=0012-2823&rft.eissn=1421-9867&rft.volume=86&rft.issue=3&rft.spage=250&rft.epage=257&rft_id=info:doi/10.1159%2F000341508&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000341508 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-2823&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-2823&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-2823&client=summon |